Jan 19, 2015

Farmak adds Metakos pharmaceutical drug to its oncology portfolio

Farmak, a leader of the domestic pharmaceutical industry, continues extending the oncology line of pharmaceutical products. Thus, Metakos, a new drug, is added to the Company’s portfolio.

This medicinal product is produced in the form of concentrate for solution for infusion (vial, 5 ml, No 1). Metakos contains zoledronic acid as active agent.

The medicinal product is prescribed for:

It is worth to remind that Farmak’s portfolio of pharmaceutical drugs for treatment of oncological diseases includes such products as Letromara (letrozole as active agent), Androfarm (cyproterone as active agent) and Flutafarm (flutamide as active agent).

Back to the News